NYSE: DBD · Application Software
Diebold Nixdorf (DBD) fair value: undervalued or overvalued?
As of 14 Nov 2026, Faircurve's model values Diebold Nixdorf (DBD) at $67.84 a share. The stock last closed at $52.87, which puts the model's fair value 28.3% above the price. On the model's bands that reads as Undervalued.
Revalued . Price is the close of 16 Nov 2026. Diebold Nixdorf, Incorporated.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 moved the fair value from $71.56 to $67.84 (-5.2%). The multiple the model anchors on moved, lowering the fair value: most of the move.
What the model makes of itThe price of $52.87 is 28.3% below it: Undervalued, on a medium evidence grade.
What's nextNext report on 11 Feb 2027. Options prices imply a move of about 14% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give DBD?
The calibrated range for DBD over 63 trading days is $45.29 to $62.20. It sits around the last close, and its width comes from the volatility that DBD's own options imply (47% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $47.46 to $91.40. In 70% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
Diebold Nixdorf, Incorporated focuses its efforts on modernizing global banking and retail interactions through comprehensive automation and digitalization. Its operations are divided into Banking and Retail.
Faircurve's model put the fair value at $67.84 a share, the midpoint of 2,000 simulations, on 14 Nov 2026. The previous run, on 7 Nov 2026, gave $71.56, so the fair value moved -5.2%. In the model's own words, the multiple it anchors on moved, lowering the fair value, which is most of the move. The calibrated range over 63 trading days is $45.29 to $62.20. Calibrated weekly on 8,038 past valuations, such ranges held the price 60% of the time at this horizon. The evidence grade is Medium. The grade looks at input completeness, the number of comparable companies and how closely they agree, and the spread of outcomes. It does not say whether the fair value is right.
Diebold Nixdorf scores 56 out of 100 on the model's quality measure, which combines six factors scored against comparable companies. Capital discipline is strongest at 85, with net buybacks of 4.6% of market value against a peer median of 0.0%. The balance sheet is weakest at 30, with net debt at 2.74x EBITDA against a peer median of 0.44x. The model compares it with Adeia, Schrödinger, BlackLine, Donnelley Financial Solutions, DoubleVerify, Sprinklr, PDF Solutions and Blackbaud.
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does DBD report earnings, and how has the stock reacted?
Diebold Nixdorf's next earnings report is scheduled for 11 Feb 2027. Companies can move their dates.
On 16 Nov 2026, DBD's 30 day implied volatility worked out to a move of about 13.5% over one month, in either direction. That is a size, not a direction.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across DBD's last 8 reports, ignoring direction, was 8.9%.
How does DBD score on business quality?
Diebold Nixdorf's overall quality score is 56 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 62 | 9.9%ROIC | 2.4% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 83 | 1.82xFCF / net income | |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 31 | 1.5%Revenue growth, trailing | 5.4% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 85 | 4.6%Net buybacks / market value | 0.0% |
| Balance sheetNet debt to EBITDA and interest coverage. | 30 | 2.74xNet debt / EBITDA | 0.44x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 34 | 4.1 ptsEBITDA margin downside volatility, 5y | 2.1 pts |
How does DBD compare with similar companies?
The companies in application software closest to Diebold Nixdorf in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| ADEA Adeia Inc. | $14.75 | $18.95 | +28.5% | Undervalued |
| SDGR Schrödinger, Inc. | $27.36 | $27.71 | +1.3% | Fairly valued |
| BL BlackLine, Inc. | $28.42 | $31.71 | +11.6% | Fairly valued |
| DFIN Donnelley Financial Solutions, Inc. | $70.06 | $78.90 | +12.6% | Fairly valued |
| DV DoubleVerify Holdings, Inc. | $13.57 | $14.91 | +9.9% | Fairly valued |
| CXM Sprinklr, Inc. | $6.79 | $7.12 | +4.9% | Fairly valued |
| PDFS PDF Solutions, Inc. | $35.15 | $34.22 | -2.6% | Fairly valued |
| BLKB Blackbaud, Inc. | $53.96 | $62.48 | +15.8% | Undervalued |
What the comparable companies' multiples alone would give for DBD, the peer-implied price, is $394.70 a share on this run. The fair value weighs that against the company's own multiple.
Diebold Nixdorf at a glance
Diebold Nixdorf, Incorporated focuses its efforts on modernizing global banking and retail interactions through comprehensive automation and digitalization. The company's operations are divided into two main areas: Banking and Retail.
- Market value
- $1.8B
- Sector
- Technology
- Industry
- Application Software
- Revenue expected, next twelve months
- $4.0B
- Consensus revenue growth, next fiscal year
- +1.5%
- Analysts with estimates
- 2
- Beta to the US market
- 0.84
- First valued by Faircurve
- 11 Jul 2026
At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. DBD was among them.
How the fair value is worked out: the model prices Diebold Nixdorf on the value of the whole business, debt included, against the revenue analysts expect next year (forward EV/Sales), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for DBD was $71.56. As of 14 Nov 2026 it is $67.84, a change of -5.2%. The multiple the model anchors on moved, lowering the fair value: most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Diebold Nixdorf's valuation
Is Diebold Nixdorf stock undervalued or overvalued?
On Faircurve's model, DBD reads as Undervalued as of 14 Nov 2026. The model's fair value is $67.84 a share against a last close of $52.87, a gap of +28.3%.
What is DBD's fair value?
$67.84 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $47.46 to $91.40.
What price range does the model give DBD?
$45.29 to $62.20 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does Diebold Nixdorf report earnings next?
The next report is scheduled for 11 Feb 2027. Companies can move their dates.
How much has DBD moved on past earnings reports?
Across its last 8 reports the median two session move was 8.9%, ignoring direction. The largest was -21.5% around the report of 29 Jul 2026.
How confident is the model in this valuation?
The model's evidence grade for DBD is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on DBD
The model holds no idea open on DBD today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on DBD with their outcomes. A free account is enough.